Medical derm

Quote












anonymous said:
Saw that the Miami position is open now? Why? He was a great rep that was a COE winner.
Click to expand...

A great rep? Hahahaha that’s funny. Only reason he won was bc of the pilot program with Clermont. Clermont never launched in Miami/s Florida before the pilot so none of the offices knew its reputation. Miami Rep kissed so much ass that he was going to win bc the company is shady as hell. They still haven’t released final numbers... isn’t that odd to anyone? Do you really think all of the 6 people that won really did win? He did do good with ximino do I’ll give you that but people in Miami can afford a $50-$75 prescription. Once the Clermont program stopped he was one of the bottom reps...., that proves the pilot was the only reason for the COE award
 








































































No incorrect Line extension ? Maybe . Fact is Marketing really has no idea what to do with it or how to make it a success. Soon a generic will appear with Lidose before 2020 ends. The LD will get what it can - then all pharmacies will move everything over to a higher priced generic with Lidose make more money less hassle then absorica and or abosorica LD. Then all of the brand will be dead. One marketing person already quit right before the launch what does that say? This LD " line extension" probably will not be a success even before the generic hits and then it will be all over. The message of why should a provider use this over Absorica is questionable. Better absorption true, but it is dosed 20 % less so what is the point we cant even answer that objection. And as we all know neither could marketing at the recent kick off meeting that from my point of view had been a waste of time.
 






anonymous said:
No incorrect Line extension ? Maybe . Fact is Marketing really has no idea what to do with it or how to make it a success. Soon a generic will appear with Lidose before 2020 ends. The LD will get what it can - then all pharmacies will move everything over to a higher priced generic with Lidose make more money less hassle then absorica and or abosorica LD. Then all of the brand will be dead. One marketing person already quit right before the launch what does that say? This LD " line extension" probably will not be a success even before the generic hits and then it will be all over. The message of why should a provider use this over Absorica is questionable. Better absorption true, but it is dosed 20 % less so what is the point we cant even answer that objection. And as we all know neither could marketing at the recent kick off meeting that from my point of view had been a waste of time.
Click to expand...
 






anonymous said:
No incorrect Line extension ? Maybe . Fact is Marketing really has no idea what to do with it or how to make it a success. Soon a generic will appear with Lidose before 2020 ends. The LD will get what it can - then all pharmacies will move everything over to a higher priced generic with Lidose make more money less hassle then absorica and or abosorica LD. Then all of the brand will be dead. One marketing person already quit right before the launch what does that say? This LD " line extension" probably will not be a success even before the generic hits and then it will be all over. The message of why should a provider use this over Absorica is questionable. Better absorption true, but it is dosed 20 % less so what is the point we cant even answer that objection. And as we all know neither could marketing at the recent kick off meeting that from my point of view had been a waste of time.
Click to expand...

at what point in 2020 can generic lidose begin to appear? I agree the meeting was a waste of time
 






anonymous said:
No incorrect Line extension ? Maybe . Fact is Marketing really has no idea what to do with it or how to make it a success. Soon a generic will appear with Lidose before 2020 ends. The LD will get what it can - then all pharmacies will move everything over to a higher priced generic with Lidose make more money less hassle then absorica and or abosorica LD. Then all of the brand will be dead. One marketing person already quit right before the launch what does that say? This LD " line extension" probably will not be a success even before the generic hits and then it will be all over. The message of why should a provider use this over Absorica is questionable. Better absorption true, but it is dosed 20 % less so what is the point we cant even answer that objection. And as we all know neither could marketing at the recent kick off meeting that from my point of view had been a waste of time.
Click to expand...

any word why the marketing person quit?
 


















Top Bottom
Back
Quote